Home›Stocks›PYXS

PYXS — structural market context

Pyxis Oncology, Inc.

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Nov 2. Each line shows the earlier value, the later value and their dates.

Price

Change from the Oct 30 close to the Nov 2 close: −6.63%.

Volume

0.99× its 20-session average on Nov 2.

Includes pre- and post-market trading.

Short interest

Short interest 4.3M shares (settlement Oct 15) vs 4.9M (Sep 30).

No new file loaded in this window. Latest file: settlement Oct 15, loaded Oct 27.

Fails-to-deliver

Latest file (settlements Sep 15–Sep 30, published Oct 16): 4 days with fails, largest 47K shares on Sep 17.

Previous file (settlements Sep 1–Sep 14, published Sep 30): 6 days with fails, largest 18K shares on Sep 9.

No new file loaded in this window.

Analyst rating actions

None recorded in this window.

Insider filings (Form 4)

None recorded in this window.

PYXS events and their magnitude

Latest SEC filing in the event study

Form 4 · purchase · filed 2026-10-09 · View on sec.gov ↗

…

How the Event Study works →

PYXS short interest & days to cover

SHARES SHORT
4.3M
% OF FLOAT
11.7%
DAYS TO COVER
3.5
CHANGE VS PRIOR
-11.1%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-10-15 (19d ago)

How short interest and days to cover are measured →

PYXS fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-09-30 · 34d31$2.9
2026-09-24 · 40d7K$3.22
2026-09-23 · 41d85$3.36

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

How fails-to-deliver are reported →

PYXS insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 0 purchases · 0 sales · 2 filings not counted

InsiderTypeSharesValueFiled
GordonMD Global Investments LP · 10 percent ownerPurchase (P)7.2M—*2026-10-09
GordonMD Global Investments LP · 10 percent ownerPurchase (P)5.5M—*2026-10-02
GordonMD Global Investments LP · 10 percent ownerPurchase (P)7.5M—*2026-10-02

*Value not shown: the filed price could not be checked against the U.S. listing.

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

Form 4 transaction codes explained →

PYXS offering filings (SEC)

4 SEC filings in the last 90 days, by filing date.

FiledFormDocument
2026-10-01Prospectus supplement filed under Rule 424(b)(5) 424B5View on sec.gov ↗
2026-09-29Prospectus supplement filed under Rule 424(b)(5) 424B5View on sec.gov ↗
2026-09-29Prospectus supplement filed under Rule 424(b)(5) 424B5View on sec.gov ↗
2026-08-20Registration statement (Form S-3) S-3View on sec.gov ↗

See all filings on SEC EDGAR ↗

SEC filings listed by filing date. A registration statement or prospectus does not by itself show that any shares were sold, how many, or at what price. Some of these filings cover debt securities or resales by existing holders. A filing is made by the issuer and appears under each of its tickers. Source: SEC EDGAR daily index; each filing links to its page on sec.gov.

Source: SEC EDGAR daily index, read once a day after the SEC publishes it (around 10:30 pm ET). Forms covered: S-1, S-3, F-1 and F-3 with their amendments, S-3ASR, F-3ASR, 424B4 and 424B5. · as of 2026-11-02

5 filings in the last 12 months.

SEC offering filings explained →

PYXS analyst ratings

FirmActionRatingPublished
H.C. WainwrightholdBuy2026-09-10
H.C. Wainwrightprice_target—2026-09-10
WedbushholdOutperform2026-09-10
Wedbushprice_target—2026-09-10
Wells FargoholdOverweight2026-09-09

Rating actions as published by the firms, from public feeds. They are not graded here.

Frequently asked questions

What is PYXS's short interest?
As of the FINRA settlement date 2026-10-15, PYXS had 4.3M shares sold short — 11.7% of its float, with 3.5 days to cover at average volume. FINRA publishes this data roughly two weeks after each twice-monthly settlement, so it is inherently delayed. A short-interest figure describes an aggregate position; it does not predict what the stock will do.
Are insiders buying PYXS?
In the last 12 months of SEC Form 4 filings, PYXS recorded 0 insider purchases and 0 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). 2 filings not counted: the filed price could not be checked against the U.S. listing. These are attributed public records — information, not instruction.
What are the SEC offering filings listed for PYXS?
They are registration statements (Forms S-1, S-3, F-1 and F-3, with their amendments and the S-3ASR and F-3ASR automatic shelf forms) and prospectuses filed under Rule 424(b)(4) or 424(b)(5). In the last 90 days the issuer of PYXS filed 4; the most recent was a prospectus supplement filed under Rule 424(b)(5) on 2026-10-01. A registration statement or prospectus does not by itself show that any shares were sold, how many, or at what price, and some of these filings cover debt securities or resales by existing holders.
What do analysts say about PYXS?
The most recent action: H.C. Wainwright hold to Buy on 2026-09-10. Rating actions are shown as published by the firms; they are not graded here.
Is this page telling me to buy or sell PYXS?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

Other companies in the same SEC industry: Pharmaceutical Preparations

ACRS · Aclaris Therapeutics, Inc.ALNY · Alnylam Pharmaceuticals, Inc.DYN · Dyne Therapeutics, Inc.KNSA · Kiniksa Pharmaceuticals InternLQDA · Liquidia CorporationNVS · Novartis AG

Industry: SIC code 2834 as recorded on SEC EDGAR.

All tickers starting with P →

PYXS: the full history

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.

Sign up with Google or emailCreate a free account